Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Notify the Multiple Myeloma Research Foundation you are interested in this trial

NCT04975555

Age 18 +

Sex Both

Phase Phase 2

Third Opinion Trial Synopsis

In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key points about the study:

The treatment involves a unique combination of therapies that have not been widely tested together before.
Patients will receive a specific regimen that includes both established and novel agents aimed at targeting the cancer more effectively.
The study aims to evaluate how well this combination works in terms of reducing cancer symptoms and improving overall health.
Participants will be closely monitored to assess the effectiveness of the treatment and any potential side effects.
This study is designed to provide insights into how combining different therapies can enhance treatment outcomes for patients.

Overall, this study represents an innovative approach to treating blood cancer, with the hope of offering new options for patients who may not have responded well to existing treatments.

Third Opinion AI Generated Synopsis

Trial Summary
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematological malignancies.

from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:

Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: